Kinnear Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Kinnear Pharmaceuticals's estimated annual revenue is currently $201k per year. 0
- Kinnear Pharmaceuticals's total funding is $3M.
Employee Data
- 00
Kinnear Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
Kinnear Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 9 | 13% | N/A | N/A |
#2 | $9.2M | 46 | 10% | N/A | N/A |
#3 | $13.7M | 68 | -1% | $362M | N/A |
#4 | $4.4M | 22 | -24% | N/A | N/A |
#5 | $1090M | 6130 | 8% | $38.4M | N/A |
#6 | $3.6M | 18 | -38% | N/A | N/A |
#7 | $0.8M | 8 | -33% | $20.7M | N/A |
#8 | $12.7M | 63 | -7% | N/A | N/A |
#9 | $0.8M | 8 | 60% | $67.6M | N/A |
#10 | $24.5M | 122 | -5% | N/A | N/A |
What Is Kinnear Pharmaceuticals?
Kinnear Pharmaceuticals is a preclinical stage pharmaceutical company committed to the discovery, development and commercialization of naturally-inspired product candidates for diseases with large unmet clinical needs. Kinnear's initial focus is the development of ceragenin-based therapies. Ceragenins are synthetic non-peptide small molecule mimetics of endogenous host defense or antimicrobial peptides. Ceragenins exhibit similar multi-faceted activities to naturally-occurring antimicrobial peptides.
keywords:N/A
$3M
Total Funding
N/A
Number of Employees
$201k
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Kinnear Pharmaceuticals News
2022-03-22 - Starzs Shining Vale: TV Review
The only way Terry (Greg Kinnear) can forgive her is to get some ... who thinks nothing of prescribing powerful pharmaceuticals to her.
Other Companies in Dublin
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $14.8M | 0 | N/A | $30M |
#2 | $0.1M | 1 | -75% | N/A |
#3 | $0M | 1 | -50% | N/A |
#4 | $0.1M | 1 | 0% | N/A |
#5 | $0.1M | 1 | 0% | N/A |